Drugs / epigallocatechin-3-gallate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05758571 | Jan → Dec 2023 | cancer, interstitial lung disease | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | epigallocatechin-3-gallate | “Thus, this study was designed to investigate the safety and efficacy of epigallocatechin-3-gallate (EGCG) aerosol to control COVID-19 pneumonia in cancer populations.” PMID 38632501 ↗ Apr 2024 |
| Known as | EGCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05758571 ↗ |